Update on results of multifield conformal radiation therapy of non-small-cell lung cancer using multileaf collimated beams

Ajay Bhatnagar, John C. Flickinger, Sanjeev Bahri, Melvin Deutsch, Chandra Belani, James D. Luketich, Joel S. Greenberger

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

We evaluated the treatment outcome for 5-field 3-dimensional conformal radiation therapy (3D-CRT) in 46 consecutive patients with unresectable, nonmetastatic non-small-cell lung cancer treated from 1993-2001. Four percent of the patients had stage I tumors, 6% had stage II, 44% had stage IIIA, and 46% had stage IIIB tumors. The median radiation therapy (RT) dose to the gross tumor volume with a median of 467.5 cc (range, 75.0-3073.0 cc) was 6120 cGy (range, 3000-6840 cGy). Thirty-one of 46 patients (67.4%) received combined chemoradiotherapy. Mean follow-up was 13.2 months (range, 3-159 months). Survival for stage III patients was 48.7% ± 9.1% at 1 year and 25.0% ± 8.4% at 2 years, with a median survival of 12.0 months ± 4.4 months. The local control rate for stage III patients was 66.8% ± 9.4% at 1 year and 28.5% ± 10.4% at 2 years. Patients who received chemotherapy had better survival (P = 0.0533) and local control (P = 0.0984) compared with patients receiving RT alone. Esophageal toxicity ≥ grade 3 was significantly greater in combined chemoradiotherapy patients (29% early, 13% late) compared to the patients receiving RT alone (0% early and late). Pulmonary toxicity (early and late) was limited to grades 1/2 in 24% of patients and early grade 3 in 2% of patients. Chemotherapy appears to improve survival and local control when added to 3D-CRT in this series. The addition of concurrent chemotherapy to RT significantly increased esophageal toxicity (within acceptable levels) and did not effect pulmonary toxicity in this series.

Original languageEnglish (US)
Pages (from-to)259-264
Number of pages6
JournalClinical Lung Cancer
Volume3
Issue number4
DOIs
Publication statusPublished - Jan 1 2002

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this